Trial · NCT07589972
Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer
NCT07589972, Not applicable, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer. Trials, record NCT07589972. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07589972
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer
- NCT number
- NCT07589972
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 45 participants, estimated
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Conditions
- Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer
- Interventions
- neoadjuvant therapy
- First posted
- 2026-05-15
- Last updated
- 2026-05-15
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total pathological complete response (tpCR) | through study completion, an average of 1 year | It indicates that no residual invasive cancer cells are detected pathologically in both primary breast lesions and axillary lymph nodes after neoadjuvant therapy and surgical operation. |
| Secondary | Event-free survival （EFS） | 5 years | The time interval from study enrollment to the occurrence of any prognosis-impacting events, including local or distant recurrence, secondary primary malignancy, and all-cause death. |
| Secondary | Objective response rate in patients undergoing neoadjuvant therapy （ORR） | through study completion, an average of 1 year | The proportion of patients who achieve remarkable tumor shrinkage meeting the criteria of partial response or complete response. |
| Secondary | Disease control rate（DCR） | through study completion, an average of 1 year | The proportion of patients with clinically controlled tumors, including those with complete response, partial response and stable disease. |
| Secondary | Invasive disease-free survival （iDFS） | 5 years | The time from surgery to invasive breast cancer recurrence, non-breast second primary tumor, or death from any cause. |
| Secondary | Relapse-free survival （RFS） | 5 years | The time from surgery to any local or distant breast cancer recurrence, excluding non-breast second primary tumors and breast cancer-unrelated mortality. |
| Secondary | Distant metastasis-free survival （DMFS） | 5 years | The time from treatment initiation to the development of distant metastasis. |
| Secondary | Overall survival （OS） | 7 years | The time from subject enrollment to all-cause death. |
| Secondary | Safety evaluation （SE） | through study completion, an average of 1 year | The proportion of patients with grade 3 or higher adverse events |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07589972
GET https://conductscience.org/api/trials/v1/NCT07589972/registered